Andrea Ferris, President and CEO of LUNGevity Foundation, shared on LinkedIn, quoting to LUNGevity Foundation’s post:
“Progress in lung cancer doesn’t happen by chance. It happens when we invest in bold ideas, talented researchers, and the partnerships that turn science into impact.
I’m proud to share 3 exciting announcements from LUNGevity Foundation that reflect our commitment to advancing research and improving outcomes for everyone affected by lung cancer.”
LUNGevity Foundation’:
“Research saves lives.
LUNGevity is proud to invest another $2 million in research to bring the next generation of breakthroughs to people affected by lung cancer. These awards will support scientists working to detect lung cancer earlier, predict which treatments are most likely to work, overcome drug resistance, and make care more precise, durable, and accessible.
The expert-vetted projects also strengthen the research workforce and advance new strategies for treating RET-positive cancers and EGFR-positive lung cancer.
We are grateful to our donors and partners for supporting these strategic lung cancer research projects that keep the patients’ needs at the center of the work.
Learn more about this important research here.”
See gallery below.
You can also read: What Changes in Lung Oncology After ESMO 2026? Survival Breakthroughs, ADC Competition, and a New Era of Precision Treatment.
